Moh’d Khushman
Assistant Professor
Oncologic Sciences
Mitchell Cancer Institute
United States of America
Biography
Dr. Moh’d Khushman joined MCI in 2015 after completing a fellowship in hematology-oncology at the University of Miami Leonard Miller School of Medicine. He has developed a clinical interest in GI malignancies and neuroendocrine tumors. A native of Jordan, Dr. Khushman earned his medical degree from the University of Jordan in Amman and completed his residency in internal medicine at Henry Ford Hospital in Detroit, where he served as chief medical resident. Dr. Khushman says he strives to provide hope to patients and aims for a cure. “In my research, I find exploring Mother Nature’s secrets a fascinating and wonderful experience,” he said. He is a member of the American Society of Clinical Oncology, the European Society of Medical Oncology, the American Society of Hematology and the American Association for Cancer Research. Dr. Khushman is board certified in Medical Oncology, Hematology and Internal Medicine.
Research Interest
GI malignancies and neuroendocrine tumors
Publications
-
Averett C, Bhardwaj A, Arora S, Srivastava SK, Khan MA, Ahmad A, Singh S, Carter JE, Khushman MD, Singh AP. Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor–stromal cross-talk. Carcinogenesis. 2016 Sep 8;37(11):1052-61.
-
Bhardwaj A, Srivastava SK, Singh S, Tyagi N, Arora S, Carter JE, Khushman MD, Singh AP. Myb promotes desmoplasia in pancreatic cancer through direct transcriptional up-regulation and cooperative action of sonic hedgehog and adrenomedullin. Journal of Biological Chemistry. 2016 Jul 29;291(31):16263-70.
-
Patel GK, Khan MA, Bhardwaj A, Srivastava SK, Zubair H, Patton MC, Singh S, Khushman MD, Singh AP. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. British Journal of Cancer. 2017 Feb 28;116(5):609-19.
-
Khushman MD, Dempsey N, Maldonado JC, Loaiza-Bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-Cordovi J, Parajuli R, Pollack T, Harwood AP. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2015 Dec 31;15(6):667-73.
